InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
6
T+90 hit rate
0%
T+90 mean return
-2.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Lingamneni Anila, Chief Technology Officer. Officer active across 2 companies, notably Haemonetics CORP. Cumulatively, 16 filings have been recorded. Split: 0 buy · 6 sells. Total volume traded: €839k. Activity tracked since 18 April 2022. The latest transaction was filed on 11 July 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations16 total
2,136 shares@ US$90.0017.1% of flowCommon StockSEC:0001127602-24-020383:0
14,140 shares0Common StockSEC:0001127602-24-016816:0
349 shares@ US$95.733.0% of flowCommon StockSEC:0001127602-24-016171:0
337 shares@ US$96.492.9% of flowCommon StockSEC:0001127602-24-015834:0
2,305 shares@ US$95.0019.6% of flowCommon StockSEC:0001127602-24-014594:0
184 shares@ US$84.881.4% of flowCommon StockSEC:0001127602-24-013101:0
2,305 shares@ US$90.0018.6% of flowCommon StockSEC:0001127602-23-024071:0
2,304 shares@ US$83.3317.3% of flowCommon StockSEC:0001127602-23-017355:0
1,385 shares@ US$83.3410.3% of flowCommon StockSEC:0001127602-23-016314:0
3,364 sharesCommon StockSEC:0001127602-23-015939:0
176 shares@ US$84.781.3% of flowCommon StockSEC:0001127602-23-013161:0
1,384 shares@ US$59.100.0030% mcap88.6% of flowCommon StockSEC:0001127602-22-015366:0
4,340 sharesCommon StockSEC:0001127602-22-014984:0
189 shares@ US$56.550.0004% mcap11.4% of flowCommon StockSEC:0001127602-22-012143:0
3,535 sharesCommon StockSEC:0001127602-21-017682
3,535 sharesCommon StockSEC:0001127602-21-017682:0
16 of 16 declarations
About Lingamneni Anila
Anila Lingamneni is the Executive Vice President and Chief Technology Officer at Haemonetics Corp, a company specializing in medical technologies. In this role, she oversees technological development and innovation within the company.
